Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical Wnt/β-catenin signaling pathway
Our study illustrated that EMPA might directly interact with FZD4 to inhibit the TAC and AngII-induced activation of the Wnt/β-catenin pathway to attenuate the adverse cardiac remodeling.
Authors
- Caixian Yang (ORCID: https://orcid.org/0000-0002-7228-1599)
- Xun Yuan (ORCID: https://orcid.org/0000-0003-4076-0517)
- Yuan Qin (ORCID: https://orcid.org/0000-0003-0205-5454)
- Guiping Zhang (ORCID: https://orcid.org/0000-0001-9818-4773)
- Zexin Huang
- Zhimei Feng
- Pan Li (ORCID: https://orcid.org/0000-0002-6902-5762)
- Ning Hou (ORCID: https://orcid.org/0000-0002-7745-4946)
- Qiulian Zhu
- Chi Zhang (ORCID: https://orcid.org/0000-0002-3554-8418)
Institutions
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-11-27
- DOI
- https://doi.org/10.3389/fphar.2024.1499542
- Citations
- 5
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- Guangzhou Medical University
- Natural Science Foundation of Guangdong Province